Collaborative Studies

Collaborative Medicinal Development (CMD) is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. The company's lead candidate, CuATSM (copper-diacetyl-bis(N4-methylthiosemicarbazone)), is a small molecule designed to deliver copper to cells with damaged mitochondria and misfolded proteins, specifically targeting the pathology of Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. CMD operates with a collaborative model, partnering with academic institutions and research organizations globally to advance its clinical programs. The company is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of CuATSM in slowing disease progression in patients with these debilitating conditions.